

THE UNIVERSITY OF CHICAGO DEPARTMENT OF MEDICINE

**Fifth Annual Clinical Cancer  
Genetics and Genomics Conference**

# **New Frontiers in Management of Inherited Cancer Syndromes**

April 8-9, 2016



**Sponsored By:**

**THE UNIVERSITY OF CHICAGO  
DEPARTMENT OF MEDICINE**

Section of Hematology and Oncology &  
Center for Clinical Cancer Genetics  
In Collaboration with The City of Hope  
Division of Clinical Cancer Genetics

**HYATT CHICAGO MAGNIFICENT MILE**  
633 N St. Clair Street  
Chicago, IL 60611

**CONFERENCE CO-DIRECTORS**

**Olufunmilayo Falusi Olopade, MD, FACP**  
Walter L. Palmer Distinguished Service Professor  
Director, Center for Clinical Cancer Genetics  
The University of Chicago

**Jeffrey N. Weitzel, MD**  
Chief, Clinical Cancer Genetics  
Professor of Oncology & Population Sciences  
City of Hope National Medical Center

**Sonia S. Kupfer, MD**  
Assistant Professor of Medicine  
Director, GI Cancer Risk and Prevention Clinic  
The University of Chicago

**Kathleen R. Blazer, EdD, MS, LCGC**  
Associate Director Cancer  
Education Program  
City of Hope National Medical Center

This educational activity is funded in part by: Center for Clinical Cancer Genetics through grants from the National Cancer Institute, Ralph and Marion Falk Medical Research Trust and families who support our efforts.



THE UNIVERSITY OF  
**CHICAGO**  
MEDICINE &  
BIOLOGICAL  
SCIENCES



## Description

This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science, discuss real-world cases, curate interesting pedigrees and prepare case summaries to disseminate new knowledge in translational genomics and evidence-based clinical management of high-risk patients and their family members. The goal is to improve detection of cancer syndromes and prevent cancer morbidity and mortality.

## Learning Objectives

After participating in this educational activity, attendees should be able to:

- Outline advanced concepts in genetics, genomics and next generation sequencing (NGS) technologies each year;
- Recognize the impact of current advances in experimental therapeutics based on germline genomics in oncology practice;
- Describe the challenges of managing affected individuals from high risk families and their at risk relatives;
- Identify appropriate clinical management of patients and at risk family members with inherited pathogenic mutations in emerging cancer susceptibility genes.

## Target Audience

This activity has been designed for physicians, physician assistants, advanced nurse practitioners, genetic counselors, oncology nurses, and other health care professionals currently involved in providing cancer genetics risk assessment services or initiating such services in their health care system. Special efforts will be made to educate clinicians practicing in geographically and/or socioeconomically underserved communities.



## Accreditation and Credit Designation

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 14.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is eligible for Category 2 CEU credit from NSGC. Please visit the MSGC website for more information.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by the ACCME, please consult your professional licensing board.

## Educational Grants/Commercial Support

Educational grant funding has been generously provided by:

**AbbVie**

**Myriad Genetic Labs**



**ADDITIONAL GENEROUS SUPPORT HAS BEEN PROVIDED  
BY OUR EXHIBITORS:**

*Elite Level*

# **Myriad Genetic Labs**

*Gold Level*

**Ambry Genetics**

**Cancer IQ**

**Invitae**

*Bronze Level*

**Gene DX**

**Genetic Task Force of Illinois**

**Hereditary Colon Cancer Foundation**

**Roche Diagnostics**



## Conference Faculty

### Conference Co-Directors

**Olufunmilayo Falusi Olopade, MD, FACP**  
Walter L. Palmer Distinguished Service Professor  
Director, Center for Clinical Cancer Genetics  
The University of Chicago

**Jeffrey N. Weitzel, MD**  
Chief, Clinical Cancer Genetics  
Professor of Oncology & Population Sciences  
City of Hope National Medical Center

**Sonia S. Kupfer, MD**  
Assistant Professor of Medicine  
Director, GI Cancer Risk and Prevention Clinic  
The University of Chicago

**Kathleen Blazer, EdD, MS, LCGC**  
Associate Director Cancer  
Education Program  
City of Hope National Medical Center

### International Guest Faculty

**William D. Foulkes, MD**  
Professor of Medicine, Human  
Genetics and Oncology  
Director, Cancer Genetics Program  
Jewish General Hospital  
Montreal, QC

**Kelly A. Metcalfe, RN, PhD**  
Professor, Lawrence S. Bloomberg  
Faculty of Nursing  
Faculty of Medicine  
Adjunct Scientist  
University of Toronto

### Guest Faculty

**Angela Bradbury, MD**  
Department of Medical Ethics and Health  
Policy Perelman School of Medicine at  
the University of Pennsylvania

**Heather Hampel, MS, LGC**  
Associate Director, Human Genetics  
Director, Biospecimen Research  
Ohio State University

**Kent Hoskins, MD**  
Associate Professor  
Hematology/Oncology  
University of Illinois

**Chanita Hughes Halbert, PhD**  
Associate Dean for Assessment and  
Evaluation  
Professor, Department of Psychiatry  
and Behavioral Sciences  
Medical University of South Carolina

**Karen Lu, MD**  
Chair and Professor  
Department of Gynecologic Oncology &  
Reproductive Medicine  
MD Anderson Cancer Center  
University of Texas

**Colin C. Pritchard, MD, PhD**  
Assistant Professor, Associate Director,  
Clinical Molecular Genetics Laboratory  
University of Washington

**Joshua D. Schiffman, MD**  
Edward B. Clark, MD Chair in  
Pediatric Research  
Professor of Pediatrics  
(Hematology/Oncology)  
Investigator, Huntsman Cancer Institute  
University of Utah

### The University Of Chicago Faculty

**Andrea Amico, MD**  
Instructor, Hematology/Oncology

**Jane Churpek, MD**  
Assistant Professor  
Hematology/Oncology

**Soma Das, PhD, FACMG**  
Director, Molecular Diagnostic Laboratory

**Lucy Godley, MD, PhD**  
Professor, Hematology/Oncology

**Neil H. Hyman, MD, FACS**  
Professor of Surgery  
Section Chief, Colon and Rectal Surgery

**Sonia S. Kupfer, MD**  
Assistant Professor of Medicine  
Director, Gastrointestinal  
Cancer Risk & Prevention Clinic

**Gillian M. Newstead, MD, FACP**  
Director of Global Breast Imaging,  
Department of Radiology

**Sarah Nielsen, MS, CGC**  
Lead Genetic Counselor  
Hematology/Oncology

**Olufunmilayo Falusi Olopade, MD, FACP**  
Professor of Medicine  
Director, Center for Clinical Cancer Genetics  
Hematology/Oncology

**Blase Polite, MD**  
Assistant Professor  
Hematology/Oncology

**Iris Romero, MD**  
Associate Professor  
Obstetrics/Gynecology

**Jessica Stoll, MS, CGC**  
Assistant Director, Gastrointestinal  
Cancer Risk and Prevention Clinic

**Caroline Weipert, MS, CGC**  
Cancer Genetic Counselor  
Hematology/Oncology

### City of Hope Faculty

**Kathleen R. Blazer, EdD, MS, CGC**  
Associate Professor  
Assistant Director, Cancer Genetics  
Education Program  
Division of Clinical Cancer Genetics  
City of Hope National Medical Center

**Jeffrey N. Weitzel, MD**  
Chief, Clinical Cancer Genetics  
Professor of Oncology &  
Population Sciences  
City of Hope National Medical Center



## DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

## COURSE FACULTY

The following individuals have disclosed no relevant financial relationships:

<b>Andrea Amico, MD</b>	<b>Chanita Hughes Halbert, PhD</b>	<b>Felicia Steverson</b>
<b>Kathleen R. Blazer, EdD, MS, CGC</b>	<b>Neil H. Hyman, MD, FACS</b>	<b>Jessica Stoll, MS, CGC</b>
<b>Travis Bray</b>	<b>Karen Lu, MD</b>	<b>Ellen G. Waller, MS</b>
<b>Alicia Cook</b>	<b>Kelly A. Metcalfe, RN, PhD</b>	<b>Caroline Weipert, MS, CGC</b>
<b>Soma Das, PhD, FACMG</b>	<b>Sarah Nielsen, MS, CGC</b>	<b>Jeffrey N. Weitzel, MD</b>
<b>William Foulkes, MD</b>	<b>Colin C. Pritchard, MD, PhD</b>	
<b>Kent Hoskins, MD</b>	<b>Iris Romero, MD</b>	

**Angela Bradbury, MD** has served as a consultant for Hill-Rom and has received research support from Myriad Genetics.

**Jane Churpek, MD** has served as an author for Up-To-Date, Inc.

**Lucy Godley, MD, PhD** has received research funding from Onconova, Inc.

**Heather Hampel, MS, LGC** has served as a consultant for Beacon LBS and GeneDx.

**Sonia S. Kupfer, MD** was a member of the data safety monitoring board (DFMO) for the University of Utah sulindac+erlotinib study. Dr. Kupfer will be speaking about off-label use of DFMO and erlotinib for polyp prevention in familial adenomatous polyposis.

**Gillian M. Newstead, MD, FACR, PhD** has received educational support from Bayer AG and served as a consultant for Bracco.

**Olufunmilayo Falusi Olopade, MD, FACP** is Co-Founder and Chief Medical Officer, CancerIQ

**Blase Polite, MD** has served as a consultant for Astra Zeneca and GLG Consulting.

**Joshua D. Schiffman, MD** is co-founder of ItRunsInMyFamily.com and Peel Therapeutics, Inc.



## UNIVERSITY OF CHICAGO CENTER FOR CONTINUING MEDICAL EDUCATION

The staff of the Center for Continuing Medical Education have no financial relationships to disclose.

### DISCLAIMER

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Copyright © 2016 University of Chicago. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from The University of Chicago Center for Continuing Medical Education.

# CONFERENCE AGENDA

## FRIDAY, APRIL 8

7:30–8:00 am	<b>Registration and Continental Breakfast</b>
8:00–8:15	<b>Welcome</b> <i>Olufunmilayo Falusi Olopade, MD, FACP, The University of Chicago Medicine</i>
	<b>HBOC Screening and Management I</b> <i>Iris Romero, MD and Sarah Nielsen, MS, CGC, Moderators</i>
8:15–9:00	<b>Keynote Address I</b> <b>Risk Reducing Strategies for Gynecologic Malignancies,</b> <i>Karen Lu, MD, MD Anderson Cancer Center</i>
9:00–9:30	<b>Topic 1: International Variation in Uptake of Cancer Risk Reduction Options in BRCA Mutation Carriers,</b> <i>Kelly A. Metcalfe, RN, PhD, University of Toronto</i>
9:30–9:50	<b>Topic 2: New Approaches to Breast Imaging</b> <i>Gillian M. Newstead MD, FACP, PhD, The University of Chicago Medicine</i>
9:50–10:30	<b>Panel Discussion with Cases</b>
10:30–11:00	<b>Break</b>
	<b>HBOC Screening and Management II</b> <i>Kathleen R. Blazer, EdD, MS, CGC, Moderator</i>
11:00–11:30	<b>Topic 1: How Genomic Technologies are Transforming Clinical Cancer Genetics,</b> <i>Colin C. Pritchard, MD, PhD, University of Washington</i>
11:30–12:00 pm	<b>Topic 2: Screening for Other Cancers in BRCA Mutation Carriers</b> <i>Kent Hoskins, MD, University of Illinois</i>
12:00–12:40	<b>Panel Discussion with Cases</b>
12:40–1:30	<b>Lunch</b>
	<b>Gastrointestinal Cancer Screening and Management</b> <i>Jessica Stoll, MS, CGC and Sonia S. Kupfer, MD, Moderators</i>
1:30–2:00	<b>Topic 1: New Frontiers in Chemoprevention for GI Cancers</b> <i>Sonia S. Kupfer, MD, The University of Chicago Medicine</i>
2:00–2:30	<b>Topic 2: Immunotherapy in Colon Cancer</b> <i>Blase Polite, MD, The University of Chicago Medicine</i>
2:30–3:00	<b>Topic 3: Choice of Surgery for Inherited Colorectal Cancer Syndromes</b> <i>Neil H. Hyman, MD, FACS, The University of Chicago Medicine</i>
3:00–3:30	<b>Panel Discussion with Cases</b>
3:30–4:00	<b>Break</b>
4:00–4:45	<b>Keynote Address II</b> <b>Population Testing for Inherited Cancer Susceptibility—From Founder Mutations to the Whole Genome,</b> <i>William D. Foulkes, MD, Jewish General Hospital, Montreal</i>
	<b>Psychosocial and Ethical Issues I</b> <i>Sarah Nielsen, MS, CGC and Caroline Weipert, MS, CGC, Moderators</i>
4:45–5:15	<b>Topic 1: Return of Actionable Clinical or Research Genomic Sequencing Results</b> <i>Angela Bradbury, MD, University of Pennsylvania</i>
5:15–6:00	<b>Voices of Advocacy</b> <i>Alicia Cook, Travis Bray, Andrea Downing and Ellen G. Waller</i>
6:00 pm	<b>Reception and Travel Awardee Poster Viewing</b>



# CONFERENCE AGENDA

## SATURDAY, APRIL 9

7:30–8:00 am	<b>Continental Breakfast</b>
7:55–8:00	<b>Announcements</b> <i>Sonia S. Kupfer, MD, The University of Chicago Medicine</i>
	<b>Psychosocial and Ethical Issues II</b> <i>Andrea Amico, MD and Jessica Stoll, MS, CGC, Moderators</i>
8:00–8:30	<b>Topic 2: Update on Reflex Testing in Colorectal Cancer Syndromes: Privacy vs. Duty to Warn</b> <i>Heather Hampel, MS, LGC, Ohio State University</i>
8:30–9:15	<b>Keynote Address III</b> <b>State of the Art In Psychosocial and Ethical Issues: Developing Culturally Tailored Interventions in High Risk Families</b> <i>Chanita Hughes Halbert, PhD, University of South Carolina</i>
9:15–10:00	<b>Panel Discussion with Cases</b>
10:00–10:30	<b>Break</b>
	<b>Updates in Pediatric Cancer Syndromes, Familial Hematologic Cancers and Li-Fraumeni</b> , <i>Jane Churpek, MD and Caroline Weipert, MS, CGC, Moderators</i>
10:30–11:15	<b>Keynote Address IV</b> <b>Translating Genomic Technologies in Pediatric Cancer</b> <i>Joshua D. Schiffman, MD, University of Utah</i>
11:15–11:45	<b>Topic 1: Management of Inherited Hematologic Malignancies</b> <i>Lucy Godley, MD, PhD, The University of Chicago Medicine</i>
11:45–12:15	<b>Topic 2: How to Manage P53 Mutations Carriers: Classic Li-Fraumeni and Incidental P53 Mutation Carriers</b> <i>Jeffrey N. Weitzel, MD, City of Hope National Medical Center</i>
12:15–1:30	<b>Lunch</b>
1:30–3:00	<b>Case Working ATM &amp; CHEK2 Families</b> <b>Current Issues in Somatic Mutation Testing</b> <i>Sarah Nielsen, MS, CGC and Sonia S. Kupfer, MD, Moderators</i>
3:00–3:20	<b>Topic 1: What Health Care Providers Need to Know When Ordering Genomic Testing for Inherited Cancer Syndromes</b> <i>Soma Das, PhD, FACMG, The University of Chicago Medicine</i>
3:20–3:50	<b>Topic 2: From Somatic to Germline — University of Chicago Experience</b> <i>Andrea Amico, MD, The University of Chicago Medicine</i>
3:50–4:10	<b>Topic 3: How Somatic Mutation Testing Impacts Treatment Choice and Experimental Therapeutics</b> <i>Olufunmilayo Falusi Olopade, MD, FACP, The University of Chicago Medicine</i>
4:10–5:00	<b>Panel Discussion with Cases</b>
5:00 pm	<b>Wrap Up</b>

Program agenda and speaker selection subject to change.